Low-Dose Naltrexone Seasonal Use Considerations

Is there a seasonal LDN dosing schedule?

Approved naltrexone runs on fixed schedules: tablets 50 mg once daily for alcohol dependence, or 25 mg then 50 mg for opioid blockade [1]; Vivitrol 380 mg by deep gluteal injection every 4 weeks [2]. LDN sits far below those doses. A 2026 narrative review describes 0.5 to 6 mg a day, most often 4.5 mg, and calls the 4.5 mg dose 'empirically derived rather than evidence-based' [3]. The labels give no guidance on LDN doses [1]. The trials used one fixed dose each: the 2013 fibromyalgia crossover trial gave 4.5 mg of LDN daily [5], the 2024 fibromyalgia trial gave 6 mg daily for 12 weeks [6], and the INNOVA trial gave 4.5 mg daily for 12 months [7].

What changes with the seasons

In one study, more than 4,000 protein-coding mRNAs in white blood cells and adipose tissue showed seasonal expression profiles, inverted between Europe and Oceania, with a pro-inflammatory profile in European winter including higher levels of soluble IL-6 receptor and C-reactive protein [8]. That study did not test LDN, and none of the LDN evidence here tests whether such seasonal changes affect response to the drug.

What the labels say all year

Both labels contraindicate naltrexone in patients receiving opioid analgesics, patients currently dependent on opioids, and patients in acute opioid withdrawal [1][2]. The tablet label recommends a minimum of 7 to 10 days opioid-free after short-acting opioids, and notes that people switching from buprenorphine or methadone may remain vulnerable to precipitated withdrawal for as long as 2 weeks [1]. Withdrawal precipitated by an opioid antagonist in an opioid-dependent person can be severe enough to require hospitalization [1]. If opioid pain relief is needed in an emergency during tablet therapy, the label says the amount of opioid required may be greater than usual and respiratory depression may be deeper and more prolonged [1].

What the LDN trials found

A 2013 crossover trial in 31 women found pain fell 28.8% on 4.5 mg daily versus 18.0% on placebo (P=0.016) [5]. Larger later trials did not repeat it: a 2024 trial in 99 women using 6 mg found a pain difference of -0.34 points (95% CI -0.95 to 0.27, p=0.27) [6], and the 12-month INNOVA trial in 98 women found an adjusted difference of 0.49 points at 3 months (p=0.236) [7]. A 2026 review of 105 studies, 15 of them randomized trials, concluded that current evidence does not support routine clinical use [3].

Compounded LDN

LDN is used off-label [3]. FDA states that compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before they are marketed [4]. A 2026 review adds that inconsistencies in compounded formulations add uncertainty [3].